Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | EVZIO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | SPRAVATO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | PHENYLKETONURIA PRODUCTS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ULTOMIRIS, PIASKY, UPLIZNA, EMPAVELI, PIASKY,RYSTIGGO, IMAAVY | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | JYNARQUE | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | HEMOPHILIA FACTOR IX | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | HEMOPHILIA FACTOR VIII | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | TOPICAL SKIN INFECTION ANTIBIOTICS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | HEREDITARY AMYLOIDOSIS PRODUCTS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | SELF-ADMINISTERED ONCOLOGY AGENTS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | EPIDIOLEX | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | THERAPEUTIC ALTERNATIVES | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | NOCDURNA (desmopressin acetate) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | QBREXZA and SOFDRA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | VYZULTA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | CRYSVITA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | XHANCE | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | COSENSI | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | LUCEMYRA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | TROGARZO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | SIKLOS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Topical NSAID (Flector, Pennsaid, Voltaren Gel) Step Therapy and Quantity Limit Criteria | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Topical Lidocaine Prior Authorization with Quantity Limit | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Topical Antibiotics and Combinations Step Therapy | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | High Cost Topical Products Prior Authorization and Quantity Limit | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Gabapentin extended-release (Horizant, Gralise) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Topical Doxepin Prior Authorization with Quantity Limit | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Products | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | YERVOY | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | MYLOTARG | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | HEMLIBRA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | BESPONSA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | CALQUENCE | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Amantadine Extended Release products | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ENDARI | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | PARATHYROID HORMONE ANALOGS FOR OSTEOPOROSIS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | LUXTURNA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ECULIZUMAB/SOLIRIS | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | CHIMERIC ANTIGEN RECEPTOR THERAPY (CAR-T CELL) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | TOPICAL DOXIPEN | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | BRIGATINIB/ALUNBRIG | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | XERMELO/TELOTRISTAL ETHYL | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | KORLYM (MIFEPRISTONE) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | AIRDUO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | RADICAVA/EDARAVONE | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ZEJULA | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | Attention Deficit [Hyperactivity] Disorder (ADHD/ADD) Agents | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | RIBOCICLIB (KISQALI) | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | AUSTEDO | New policy |
| Aug 2, 2026 | Blue Cross and Blue Shield of Nebraska | ETELCALCETIDE (PARSABIV) | New policy |